Moderna, Inc.

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-17 EDT			5-day change	1st Jan Change
124.1 ^USD	-0.87%		+5.63%	+24.74%

07-17	EU court criticizes Commission over handling of COVID vaccine contracts	RE
07-15	Moderna Insider Sold Shares Worth $1,756,177, According to a Recent SEC Filing	MT

Moderna announces FDA has given full approval to its COVID-19 vaccine after reviewing more data on safety, effectiveness

January 31, 2022 at 11:17 am

WASHINGTON (AP) — Moderna announces FDA has given full approval to its COVID-19 vaccine after reviewing more data on safety, effectiveness.

Latest news about Moderna, Inc.

EU court criticizes Commission over handling of COVID vaccine contracts	07-17	RE
Moderna Insider Sold Shares Worth $1,756,177, According to a Recent SEC Filing	07-15	MT
China approves CSPC Pharma's RSV vaccine for clinical trials	07-11	RE
Flagship Pioneering Raises $3.6B for 'New Wave' of Health, AI Innovation	07-10	MT
Redburn Raises Moderna's Price Target to $117 From $116	07-10	MT
Bird flu response in Michigan sparks COVID-era worry on farms	07-10	RE
Moderna: partnership for mRNA vaccines in Japan	07-09	CF
Moderna Partners With Mitsubishi Tanabe Pharma to Promote Vaccines in Japan	07-09	MT
Moderna and Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna?s Mrna Respiratory Vaccine Portfolio in Japan, Including Covid-19 Vaccines	07-08	CI
HilleVax to discontinue development of norovirus vaccine for infants; shares plummet	07-08	RE
Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births	07-08	RE
Moderna, Pfizer-BioNTech COVID-19 Vaccine Patent Legal Battle Gets Mixed UK Ruling	07-02	MT
Pfizer-BioNTech, Moderna Set to Appeal Mixed UK Ruling in COVID-19 Vaccine Patent Case	07-02	MT
Moderna: grant for influenza vaccine	07-02	CF
Moderna Receives $176 Million Award to Boost Development of mRNA-Based Pandemic Flu Vaccine	07-02	MT
UK court gives mixed ruling in Pfizer v Moderna COVID vaccine patents case	07-02	RE
Analysis-Scientists wary of bird flu pandemic 'unfolding in slow motion'	07-01	RE
Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell 1000 Value-Defensive Index	06-30	CI
Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell 1000 Defensive Index	06-30	CI
Moderna: positive CHMP opinion on RSV	06-28	CF
Wall Street Set to Open Higher Friday as Key Inflation Data Indicates Cooling Inflation	06-28	MT
Sector Update: Health Care Stocks Higher Pre-Bell Friday	06-28	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Ahead of Key Inflation Report	06-28	MT
Sector Update: Health Care	06-28	MT
Moderna Secures European Medicines Agency's Positive Opinion for mRESVIA	06-28	MT

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).

Sector

Biotechnology & Medical Research

Calendar

2024-08-01 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says

June 12, 2024 at 03:38 pm

Moderna, Inc. prepares for the post-Covid era

March 25, 2024 at 10:24 am

Stéphane Bancel, CEO of Moderna: Restoring confidence in the vaccines sector

January 16, 2024 at 03:31 pm

More Strategies

Ratings for Moderna, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

124.1 USD

Average target price

145.9 USD

Spread / Average Target

+17.61%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+24.74%	47.54B
IQVIA HOLDINGS INC.	-0.47%	41.96B
LONZA GROUP AG	+48.83%	41.55B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	30.36B
ICON PUBLIC LIMITED COMPANY	+17.96%	27.61B
CELLTRION, INC.	-4.47%	28.7B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.7B
MEDPACE HOLDINGS, INC.	+42.56%	13.51B
BIO-TECHNE CORPORATION	+1.46%	12.34B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-5.60%	11.49B

Other Biotechnology & Medical Research

Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Moderna announces FDA has given full approval to its COVID-19 vaccine after reviewing more data on safety, effectiveness

Latest news about Moderna, Inc.

Chart Moderna, Inc.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Moderna, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research